Hoppa till huvudinnehåll
Blood Test

Nytt blodprov kan upptäcka aggressiv prostatacancer

Enligt forskning från Queen Mary University of London har ett nytt blodprov visat sig kunna upptäcka förekomsten av aggressiv prostatacancer med hög precision.

Looking for home psa testing?

Get expert healthcare advice from the comfort of home. Complete a quick online consultation, available 24/7, with your request reviewed by a UK-registered clinician. Next day delivery available on eligible treatments.

By combining the current prostate specific antigen (PSA) test with the new test (the circulating tumour cell (CTC) test, this could help men avoid unnecessary and invasive biopsies, over-diagnosis and over-treatment.

Prostate cancer is currently detected using a blodprov that measures PSA levels. Although it provides early diagnosis, 75% of all PSA positive results ending up with negative biopsies that do not find cancer.

The study, published in the Journal of Urology, looked at the use of the CTC test in almost 100 pre-biopsy patients and over 150 newly diagnosed prostate cancer patients at St Bartholomew's Hospital in London.

The research team found that the presence of CTCs in pre-biopsy blood samples was indicative of the presence of aggressive prostate cancer, and efficiently and non-invasively predicted the later outcome of biopsy results.

When the CTC tests were used in combination with the current PSA test, it was able to predict the presence of aggressive prostate cancer in other biopsies with over 90% accuracy.

The test could also show how aggressive the cancer is. Focusing on more aggressive prostate cancer may reduce overtreatment and unnecessary biopsies for benign and non-aggressive conditions.

Lead researcher Professor Yong-Jie Lu from Queen Mary University of London said: "The current prostate cancer test often leads to unnecessary invasive biopsies and over-diagnosis and over-treatment of many men, causing significant harm to patients and a waste of valuable healthcare resources. There is clearly a need for a better selection process for patients to undergo the biopsy procedure.

"Testing for circulating tumour cells is efficient, non-invasive and potentially accurate, and we've now demonstrated its potential to improve the current standard of care. By combining the new CTC analysis with the current PSA test, we were able to detect prostate cancer with the highest level of accuracy ever seen in any biomarker test, which could spare many patients unnecessary biopsies. This could lead to a paradigm shift in the way we diagnose prostate cancer," he added.

Due to the small sample size, the findings will need to be validated by further studies. However, researchers said the CTC test could be available on the NHS in as little as three years if successful.

Sara Hiom, Cancer Research UK's director of early diagnosis, said: "It's early days, so the next steps would be to study a larger number of people."

Looking for home psa testing?

Get expert healthcare advice from the comfort of home. Complete a quick online consultation, available 24/7, with your request reviewed by a UK-registered clinician. Next day delivery available on eligible treatments.

Artikelhistorik

Informationen på denna sida är granskad av kvalificerade kliniker.
  • 16 sept 2019 | Ursprungligen publicerad

    Författad av:

    Ashwin Bhandari

    Granskad av

    Joe Crowther

Delta i konversationen

Dela dina tankar eller erfarenheter med andra i vår patientgemenskaper.

Relaterade diskussioner

Visa fler diskussioner
Ansvarsfriskrivning: The views expressed in the community do not represent medical advice. For any health concerns, consult your GP or healthcare provider.

Onlineapotek, behandlingar och hälsotjänster

Enkel tillgång till pålitliga behandlingar och hälsotjänster online.

Common conditions

Get help with common conditions through the NHS, without a GP appointment.

Book your free Pharmacy First appointment

Anmäl dig till Patientens nyhetsbrev

Din veckovisa dos av tydliga, pålitliga hälsoråd - skrivna för att hjälpa dig känna dig informerad, självsäker och i kontroll.

Vänligen ange en giltig e-postadress

Genom att prenumerera accepterar du våra Sekretesspolicy. Du kan avsluta prenumerationen när som helst. Vi säljer aldrig dina uppgifter.